Update 2021-08-20 since this is getting more attention: Shortly after I wrote this post, the FDA backtracked a bit, and restricted the indication to only early-stage Alzheimer’s patients. This means that it’s unlikely aducanumab will cost $100 billion per year. Still, it could be extremely expensive.
A Travesty at the FDA
Update 2021-08-20 since this is getting more attention: Shortly after I wrote this post, the FDA backtracked a bit, and restricted the indication to only early-stage Alzheimer’s patients. This means that it’s unlikely aducanumab will cost $100 billion per year. Still, it could be extremely expensive.
Create your profile
Only paid subscribers can comment on this post
Check your email
For your security, we need to re-authenticate you.
Click the link we sent to , or click here to sign in.